Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cerilliant
Healthtrust
Fish and Richardson
Queensland Health
Boehringer Ingelheim
Deloitte
Accenture
QuintilesIMS
Citi
AstraZeneca

Generated: February 18, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,414,105

« Back to Dashboard

Summary for Patent: 7,414,105
Title:Peptides that bind to the erythropoietin receptor
Abstract: The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention also relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, are also provided.
Inventor(s): Holmes; Christopher P. (Saratoga, CA), Yin; Qun (Palo Alto, CA), Lalonde; Guy (Woodside, CA), Schatz; Peter J. (Cupertino, CA), Tumelty; David (Sunnyvale, CA), Palani; Balu (Cupertino, CA), Zemede; Genet (Santa Clara, CA)
Assignee: Affymax, Inc. (Palo Alto, CA)
Application Number:11/261,157
Patent Claim Types:
see list of patent claims
Compound; Use; Composition;

Drugs Protected by US Patent 7,414,105

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Takeda Pharms Usa OMONTYS peginesatide acetate SOLUTION;INTRAVENOUS, SUBCUTANEOUS 202799-007 Mar 27, 2012 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial Y Y TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE ➤ Try a Free Trial
Takeda Pharms Usa OMONTYS peginesatide acetate SOLUTION;INTRAVENOUS, SUBCUTANEOUS 202799-008 Mar 27, 2012 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial Y Y TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE ➤ Try a Free Trial
Takeda Pharms Usa OMONTYS PRESERVATIVE FREE peginesatide acetate SOLUTION;INTRAVENOUS, SUBCUTANEOUS 202799-001 Mar 27, 2012 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial Y Y TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE ➤ Try a Free Trial
Takeda Pharms Usa OMONTYS PRESERVATIVE FREE peginesatide acetate SOLUTION;INTRAVENOUS, SUBCUTANEOUS 202799-002 Mar 27, 2012 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial Y Y TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE ➤ Try a Free Trial
Takeda Pharms Usa OMONTYS PRESERVATIVE FREE peginesatide acetate SOLUTION;INTRAVENOUS, SUBCUTANEOUS 202799-003 Mar 27, 2012 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial Y Y TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE ➤ Try a Free Trial
Takeda Pharms Usa OMONTYS PRESERVATIVE FREE peginesatide acetate SOLUTION;INTRAVENOUS, SUBCUTANEOUS 202799-004 Mar 27, 2012 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial Y Y TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE ➤ Try a Free Trial
Takeda Pharms Usa OMONTYS PRESERVATIVE FREE peginesatide acetate SOLUTION;INTRAVENOUS, SUBCUTANEOUS 202799-005 Mar 27, 2012 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial Y Y TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE ➤ Try a Free Trial
Takeda Pharms Usa OMONTYS PRESERVATIVE FREE peginesatide acetate SOLUTION;INTRAVENOUS, SUBCUTANEOUS 202799-006 Mar 27, 2012 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial Y Y TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 7,414,105

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,084,245 Peptides that bind to the erythropoietin receptor ➤ Try a Free Trial
7,855,175 Peptides that bind to the erythropoietin receptor ➤ Try a Free Trial
8,729,030 Peptides that bind to the erythropoietin receptor ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 7,414,105

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Singapore 160224 ➤ Try a Free Trial
Serbia 51130 ➤ Try a Free Trial
Serbia 20050838 ➤ Try a Free Trial
Portugal 1629007 ➤ Try a Free Trial
African Intellectual Property Organization (OAPI) 13164 ➤ Try a Free Trial
New Zealand 543905 ➤ Try a Free Trial
Norway 338435 ➤ Try a Free Trial
Norway 20055852 ➤ Try a Free Trial
Mexico PA05012316 ➤ Try a Free Trial
Montenegro P53308 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Citi
Federal Trade Commission
AstraZeneca
Johnson and Johnson
US Department of Justice
Healthtrust
McKesson
Cantor Fitzgerald
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot